Immuno-oncology (IO) has brought a revolution to cancer treatment. Unlike many current cancer treatment approaches, including chemotherapy, radiation, and targeted therapy which aim to kill cancer cells directly, immunotherapy activates and enhances the patient’s immune system to kill cancer cells. Immunotherapy results in long-lasting efficacy and is relatively safe compared to most other cancer treatments.
Cancer immunotherapy includes immune checkpoint inhibitors, chimeric antigen receptor (CAR)-T/NK immune cell therapy, cancer vaccines, and oncolytic virus. Ipilimumab, Opdivo, Keytruda, Libtayo, Tencentriq, Imfinzi and Bavencio have all been very successful drugs recently entering the market targeting immune checkpoints, such as CTLA-4 and PD-1/PD-L1. Clearly, this is just the beginning of a rapidly expanding of immunotherapy targeting unmet needs for cancer treatment. With our experienced team, L&L Biopharma is dedicated to discovering new immunotherapy candidates and products, including bispecific and tri- specific antibodies and combinations of immunotherapies for patients who are resistant or refractory with PD-1/PD-L1 treatments.
Currently, we have four programs ongoing and several others in incubation. Two of our ongoing projects are bispecific antibodies to target immune checkpoints and CD8 T cells which are in phase I study. The other tri-specific antibodies and two out-licensed bispecific products are in IND enabling.
不同于传统的化疗、以及靶向治疗，肿瘤免疫（Immune Oncology, IO）治疗不直接靶向肿瘤细胞，而是调动病人自身的免疫系统来攻击肿瘤细胞。具有安全、有效效应时间长、精准、广谱等特点。针对immune checkpoints 的单克隆抗体药物ipilimumab (CTLA-4 单克隆抗体药物), Opdivo、keytruda、Libtayo (PD-1 单克隆抗体药物), 以及Tecentriq、Imfinzi、Bavencio (PD-L1 单克隆抗体药物) 一经获批，市场销售迅猛增长，预示癌症免疫治疗研发进入了黄金时期，成为生物医药领域的顶级风口。肿瘤免疫治疗亦可能成为癌症治疗的支柱产业。
IO药物开发因此异常活跃，产品涵盖了多种形式，包括单克隆抗体、融合蛋白、细胞因子、双特异性抗体分子、嵌合抗原受体 T 细胞疗法（CAR-T），溶瘤病毒、小分子等。我们公司把握肿瘤免疫治疗创新前沿，集中力量，专注双特异抗体，三特异抗体及联合治疗方法/药物前期产品研发和产品授权转让。 这些产品聚焦PD-1后时代，耐药和无效人群临床刚需。
Cancer immunotherapy includes immune checkpoint inhibitors, chimeric antigen receptor (CAR)-T/NK immune cell therapy, cancer vaccines, and oncolytic virus. Ipilimumab, Opdivo, Keytruda, Libtayo, Tencentriq, Imfinzi and Bavencio have all been very successful drugs recently entering the market targeting immune checkpoints, such as CTLA-4 and PD-1/PD-L1. Clearly, this is just the beginning of a rapidly expanding of immunotherapy targeting unmet needs for cancer treatment. With our experienced team, L&L Biopharma is dedicated to discovering new immunotherapy candidates and products, including bispecific and tri- specific antibodies and combinations of immunotherapies for patients who are resistant or refractory with PD-1/PD-L1 treatments.
Currently, we have four programs ongoing and several others in incubation. Two of our ongoing projects are bispecific antibodies to target immune checkpoints and CD8 T cells which are in phase I study. The other tri-specific antibodies and two out-licensed bispecific products are in IND enabling.
不同于传统的化疗、以及靶向治疗，肿瘤免疫（Immune Oncology, IO）治疗不直接靶向肿瘤细胞，而是调动病人自身的免疫系统来攻击肿瘤细胞。具有安全、有效效应时间长、精准、广谱等特点。针对immune checkpoints 的单克隆抗体药物ipilimumab (CTLA-4 单克隆抗体药物), Opdivo、keytruda、Libtayo (PD-1 单克隆抗体药物), 以及Tecentriq、Imfinzi、Bavencio (PD-L1 单克隆抗体药物) 一经获批，市场销售迅猛增长，预示癌症免疫治疗研发进入了黄金时期，成为生物医药领域的顶级风口。肿瘤免疫治疗亦可能成为癌症治疗的支柱产业。
IO药物开发因此异常活跃，产品涵盖了多种形式，包括单克隆抗体、融合蛋白、细胞因子、双特异性抗体分子、嵌合抗原受体 T 细胞疗法（CAR-T），溶瘤病毒、小分子等。我们公司把握肿瘤免疫治疗创新前沿，集中力量，专注双特异抗体，三特异抗体及联合治疗方法/药物前期产品研发和产品授权转让。 这些产品聚焦PD-1后时代，耐药和无效人群临床刚需。
Scheme of L&L Biopharma Products
|